SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery
Status:
Not yet recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The goal of this mechanistic clinical trial is to learn about the effects of medications
called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and
brain injury in patients having heart surgery. The main questions it aims to answer are:
1. Does soluble guanylyl cyclase stimulation improve blood vessel function compared to
placebo?
2. Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain
injury compared to placebo?
Participants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or
placebo, and researchers will compare vascular function and markers of brain and kidney
injury to see if vericiguat improves vascular function and reduces markers of injury.
This will provide important information to determine the underlying reasons that patients
have some kidney and brain function problems after having heart surgery.